3:19 PM
Mar 12, 2018
 |  BC Extra  |  Company News

Nektar joining S&P 500

Nektar Therapeutics (NASDAQ:NKTR) is joining the Standard & Poor’s 500 index, effective March 19.

The news comes a few weeks after Nektar partnered with Bristol-Myers Squibb Co. (NYSE:BMY) to develop and commercialize Nektar's NKTR-214 in combination with BMS's anti-PD-1 mAb Opdivo nivolumab and Opdivo plus the pharma’s Yervoy ipilimumab in select solid tumors (see BioCentury, March 2).

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD